1022964-14-2

Upstream product

• 3400-29-1 N-methyl-2-nitrobenzamide 
• 610-14-0 2-nitrobenzyl chloride 
• 118-48-9 isatoic anhydride 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 4141-08-6 2-Amino-N-methylbenzamid 

Downstream Products

• 1022964-09-5 2-[2-(3-ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamino)-5-methyl-pyrimidin-4-ylamino]-N-methyl-benzamide 
• 1089653-58-6 N-methyl-2-[(5-methyl-2-{[6-(4-methyl-1-piperazinyl)-3-pyridinyl]amino}-4-pyrimidinyl)amino]benzamide hydrochloride 

Relevant academic research and scientific papers

Aminodithioformate compound used as FAK inhibitor

A purpose of the invention is to provide an aminodithioformate compound serving as an FAK inhibitor, a pharmaceutical composition, a preparation method and applications thereof, wherein the compound has a structure represented by the following general formula (I).

Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities

A series of 2,4-diarylaminopyrimidine derivatives containing dithiocarbamate moiety were designed by molecular hybridization strategy and synthesized for screening as inhibitors of focal adhesion kinase (FAK). Most of these compounds exhibit significant a

ANTHRANILAMIDE INHIBITORS OF AURORA KINASE

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

ANTHRANILAMIDES

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, and Het are as defined herein. Compounds of the present invention are useful as Aurora kinase inhibitors.

FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.